Skip to main content

A Brief History of Amyloidosis

  • Chapter
  • First Online:
Cardiac Amyloidosis

Abstract

Amyloidoses are disorders due to gene mutations, aging, or systemic diseases leading to the extracellular deposition of fibrillar proteins, which cause morphological and functional alterations of tissues. The term “amyloid” was introduced in the nineteenth century by the German botanist Matthias Schleiden, who firstly used a histochemical staining reaction by iodine and sulfuric acid allowing the detection of starch (ἄμυλον in Greek, “amylum” in Latin) in plants. Then the German physician and physiologist Rudolf Virchow (1821–1902) introduced the term “amyloid” in the medical literature. While Virchow believed that these tissue deposits had the same composition of starch, during the second half of the nineteenth century it was assessed that they are composed of proteins. In 1922, Congo red staining was found to mark amyloid deposits. The reactivity with Congo red staining, i.e., congophilia with apple green birefringence under polarized light was the first diagnostic criterion for amyloid, and it is still relevant for diagnosis. From the second half of the twentieth century, electron microscopy allowed to characterize the ultrastructure of amyloid deposits. Furthermore, a growing number of proteins were identified as possible precursors of amyloid deposits. The most recent and significant developments in the field of amyloidosis are represented by either the introduction of new diagnostic techniques or the identification of therapies interfering with specific steps of the amyloidogenic cascade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AL:

Amyloid light chain amyloidosis

ATTR:

Amyloid transthyretin amyloidosis (v, variant; wt, wild-type)

ATTR-ACT:

Tafamidis in transthyretin cardiomyopathy clinical trial

CA:

Cardiac amyloidosis

PET:

Positron emission tomography

References

  1. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–54.

    Article  CAS  PubMed  Google Scholar 

  2. Tanskanen M. “Amyloid”—historical aspects. In: Feng D, editor. Amyloidosis [Internet]. London: IntechOpen; 2013. [cited 2022 Dec 27]. https://www.intechopen.com/chapters/44870. https://doi.org/10.5772/53423.

    Chapter  Google Scholar 

  3. Scleiden MJ, Schwann T, Schulze M. Klassische Schriften zur Zellenlehre. In: Ostwalds klassiker der exakten Wissenschaften, band 275: Verlag Harri Deutsch. http://ww.books.google/fi/books/about/Klassische_Schriften_zur_Zellenlehre.html?=h9_WFhLD8uYC&redir_esc=y.

  4. Virchow R. Über eine im Gehirn und Rückenmark des Menschen aufgefundene Substanz mit der chemischen Reaction der Cellulose. Virchows Archiv Pathol Anat Klinische Med Berlin. 1854;6:135–8.

    Article  Google Scholar 

  5. Kyle RA. Amyloidosis: a convoluted story. Br J Haematol. 2001;114:529–38.

    Article  CAS  PubMed  Google Scholar 

  6. SteensmaDP. “Congo” red: out of Africa? Arch Pathol Lab Med. 2001;125:250–2.

    Article  Google Scholar 

  7. Bennhold H. Eine spezifische Amyloidfärbung mit Kongorot. Münchener Medizinische Wochenschrift (November) 1922:1537–1538.

    Google Scholar 

  8. Divry P. Etude histo-chimique des plaques seniles. J de Neurologie et de Psychiatrie. 1927;27:643–57.

    Google Scholar 

  9. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem. 1962;10:355–64.

    Article  CAS  Google Scholar 

  10. Yakupova EI, Bobyleva LG, Vikhlyantsev IM, Bobylev AG. Congo red and amyloids: history and relationship. Biosci Rep. 2019;39:BSR20181415.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschr Psychtiatr Psych Gerichtl Med. 1907;64:146–8.

    Google Scholar 

  12. Cohen AS, Calcins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature. 1959;183:1202–3.

    Article  CAS  PubMed  Google Scholar 

  13. Glenner GG, Bladen HA. Purification and reconstitution of the periodic fibril and unit structure of human amyloid. Science. 1966;154:271–2.

    Article  CAS  PubMed  Google Scholar 

  14. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterization of soluble amyloid prepared in water. J Clin Invest. 1968;47:924–33.

    Article  CAS  PubMed  Google Scholar 

  15. Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem. 1968;16(11):673–7.

    Article  CAS  PubMed  Google Scholar 

  16. Bonar L, Cohen AS, Skinner MM. Characterization of the amyloid fibril as a crossbeta protein. Proc Soc Exp Biol Med. 1969;131:1373–5.

    Article  CAS  PubMed  Google Scholar 

  17. Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science. 1971;172:1150–1.

    Article  CAS  PubMed  Google Scholar 

  18. Bendit EP, Eriksen N. Chemical similarity among amyloid substances associated with long standing inflammation. Lab Investig. 1971;26:615–25.

    Google Scholar 

  19. Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A. 1978;75:4499–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Corino de Andrade M. Preliminary note on an unusual form of peripheral neuropathy. Rev Neurol. 1951;85:302–6.

    Google Scholar 

  21. Meretoja J. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res. 1969;1:314–24.

    CAS  PubMed  Google Scholar 

  22. Sletten K, Westermark P, Natvig JB. Senile cardiac amyloid is related to prealbumin. Scand J Immunol. 1980;12:503–6.

    Article  CAS  PubMed  Google Scholar 

  23. Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM, Sekijima Y, Westermark P. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022, 29:213–9.

    Google Scholar 

  24. Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010;1804:1405–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wisniowski B, Wechalekar A. Confirming the diagnosis of amyloidosis. Acta Haematol. 2020;143:312–21.

    Article  CAS  PubMed  Google Scholar 

  26. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–84.

    Article  PubMed  Google Scholar 

  27. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12.

    Article  CAS  PubMed  Google Scholar 

  28. Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, Panichella G, Sinagra G, Merlo M, Fontana M, Gillmore J, Quarta CC, Maurer MS, Kittleson MM, Garcia-Pavia P, Emdin M. Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:1288–303.

    Article  PubMed  Google Scholar 

  29. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet. 1988;1:1413–8.

    Article  CAS  PubMed  Google Scholar 

  30. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508–13.

    Article  CAS  PubMed  Google Scholar 

  31. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69:1471–84.

    Article  CAS  PubMed  Google Scholar 

  32. Genovesi D, Vergaro G, Giorgetti A, Marzullo P, Scipioni M, Santarelli MF, Pucci A, Buda G, Volpi E, Emdin M. [18F]-Florbetaben PET/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imaging. 2021;14:246–55.

    Article  PubMed  Google Scholar 

  33. Kyle RA, Wagoner RD, Holley KE. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med. 1982;142:1445–7.

    Article  CAS  PubMed  Google Scholar 

  34. Majolino I, Marcenò R, Pecoraro G, et al. High-dose therapy and autologous transplantation in amyloidosis-AL. Haematologica. 1993;78:68–71.

    CAS  PubMed  Google Scholar 

  35. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL, ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46–58.

    Article  CAS  PubMed  Google Scholar 

  37. Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847–54.

    Article  CAS  PubMed  Google Scholar 

  38. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16.

    Article  CAS  PubMed  Google Scholar 

  40. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42:1554–68.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O’Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385:493–502.

    Article  CAS  PubMed  Google Scholar 

  42. Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res. 2021;128:1554–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Assuero Giorgetti .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Giorgetti, A., Pucci, A., Aimo, A. (2024). A Brief History of Amyloidosis. In: Emdin, M., Vergaro, G., Aimo, A., Fontana, M. (eds) Cardiac Amyloidosis. Springer, Cham. https://doi.org/10.1007/978-3-031-51757-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-51757-0_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-51756-3

  • Online ISBN: 978-3-031-51757-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics